In WAYPOINT, tezepelumab produced early and sustained improvements in patient-reported and objective smell outcomes compared with placebo, and markedly reduced the proportion of patients with UPSIT-defined anosmia.
Objective Patterns of Olfactory Impairment and Reduced Olfactory Threshold Shown in Patients with Uncontrolled Chronic Rhinosinusitis
Patients with uncontrolled chronic rhinosinusitis (CRS) demonstrate distinct patterns of olfactory impairment, and a reduced olfactory threshold is highly associated with uncontrolled CRS.